Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide red; maize starch; microcrystalline cellulose; magnesium stearate; hyprolose - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: hyprolose; maize starch; microcrystalline cellulose; magnesium stearate; lactose monohydrate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; hyprolose; iron oxide yellow; maize starch; microcrystalline cellulose; lactose monohydrate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; hyprolose; lactose monohydrate; microcrystalline cellulose; indigo carmine aluminium lake - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - jynarque is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (adpkd). jynarque is contraindicated in patients: - with a history, signs or symptoms of significant liver impairment or injury. this contraindication does not apply to uncomplicated polycystic liver disease [see warnings and precautions (5.1)] - taking strong cyp 3a inhibitors - with uncorrected abnormal blood sodium concentrations [see warnings and precautions (5.3)] - unable to sense or respond to thirst [see warnings and precautions (5.3)] - hypovolemia [see warnings and precautions (5.3)] - hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product [see adverse reactions (6)] - uncorrected urinary outflow obstruction - anuria risk summary available data with jynarque use in pregnant women are insufficient to determine if there is a drug associated risk of adverse developmental outcomes. in embryo-fetal development studies, pregnant rats a

United States - English - NLM (National Library of Medicine)

vedco - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - for use as an aid in the treatment of acetonemia (ketosis) in cattle. for animal use only

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

luen wah medical co. sdn. bhd. - dextrose, anhydrous/anhydrous glucose -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

luen wah medical co. sdn. bhd. - sodium chloride (salt); dextrose, anhydrous/anhydrous glucose -

Singapore - English - HSA (Health Sciences Authority)

nagase singapore (pte) ltd. - microbiology - an in vitro diagnostic device to measure changes in 13co2 content in breath co2 gas by infrared spectroscopic analysis. intended for use in conjunction with commercially available 13c-urea breath tests for the detection of helicobacter pylori (h. pylori) infection. suitable for use in both point of care and clinical laboratory settings.

Singapore - English - HSA (Health Sciences Authority)

nagase singapore (pte) ltd. - microbiology - the poconeplus infrared spectrophotometer is an in vitro diagnostic medical device designed to measure changes in the 13co2 content in breath co2 gas by infrared spectroscopic analysis.